Literature DB >> 14638619

Hypertension treatment and control in five European countries, Canada, and the United States.

Katharina Wolf-Maier1, Richard S Cooper, Holly Kramer, José R Banegas, Simona Giampaoli, Michel R Joffres, Neil Poulter, Paola Primatesta, Birgitta Stegmayr, Michael Thamm.   

Abstract

Levels of hypertension treatment and control have been noted to vary between Europe and North America, although direct comparisons with similar methods have not been undertaken. In this study, we sought to estimate the relative impact of hypertension treatment strategies in Germany, Sweden, England, Spain, Italy, Canada, and the United States by using sample surveys conducted in the 1990s. Hypertension was defined as a blood pressure of 160/95 mm Hg or 140/90 mm Hg, plus persons taking antihypertensive medication. "Controlled hypertension" was defined as a blood pressure less than threshold among persons taking antihypertensive medications. Among persons 35 to 64 years, 66% of hypertensives in the United States had their blood pressure controlled at 160/95 mm Hg, compared with 49% in Canada and 23% to 38% in Europe. Similar discrepancies were apparent at the 140/90 mm Hg threshold, at which 29% of hypertensives in the United States, 17% in Canada, and </=10% in European countries had their blood pressure controlled. At the 140/90 mm Hg cutpoint, two thirds to three quarters of the hypertensives in Canada and Europe were untreated compared with slightly less than half in the United States. Although guidelines vary among countries, resulting in different case definitions, this does not account entirely for the varying success of different national control efforts. Low treatment and control rates in Europe, combined with a higher prevalence of hypertension, could contribute to a higher burden of cardiovascular disease risk attributable to elevated blood pressure compared with that in North America.

Entities:  

Mesh:

Year:  2003        PMID: 14638619     DOI: 10.1161/01.HYP.0000103630.72812.10

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  285 in total

1.  Prevalence of hypertension, its awareness and control in adult population in Japan.

Authors:  A Sekikawa; T Hayakawa
Journal:  J Hum Hypertens       Date:  2004-12       Impact factor: 3.012

2.  Guidelines from the British Hypertension Society.

Authors:  Stéphane Laurent
Journal:  BMJ       Date:  2004-03-13

3.  Renal intervention to treat hypertension.

Authors:  Rajan A G Patel; Christopher J White
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

Review 4.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

5.  Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010.

Authors:  Christoph Gensch; Uta Hoppe; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2010-12-23       Impact factor: 5.460

6.  Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial.

Authors:  Nudrat Noor Qureshi; Juanita Hatcher; Nish Chaturvedi; Tazeen H Jafar
Journal:  BMJ       Date:  2007-11-08

7.  Hypertensive Disorders of Pregnancy - A Life-Long Risk?!

Authors:  C E Schausberger; V R Jacobs; G Bogner; P Wolfrum-Ristau; T Fischer
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-01       Impact factor: 2.915

8.  Self-monitoring of blood pressure for improving adherence to antihypertensive medicines and blood pressure control: a randomized controlled trial.

Authors:  Masumeh Hosseininasab; Zahra Jahangard-Rafsanjani; Abbas Mohagheghi; Amir Sarayani; Arash Rashidian; Mohammadreza Javadi; Alireza Ahmadvand; Molouk Hadjibabaie; Kheirollah Gholami
Journal:  Am J Hypertens       Date:  2014-04-26       Impact factor: 2.689

Review 9.  Combination drug treatment of hypertension: have we come full circle?

Authors:  Addison A Taylor
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 10.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.